Newsletter - May 21, 2020
Moderna and Gilead Teach the “Value for Speed” in Pharma
About a month ago, it was being predicted that a treatment for COVID-19 may take several months and a vaccine may not be available for 12-18 months. These predictions got kicked with the emergency approval of Gilead’s remdesivir, and positive results from Moderna’s vaccine trial run by NIH, and this is not by chance. Read More
Physician’s Perspective in Using Clinical Trials Data in Patient Care
Physicians are often coaxed by their patients to try the latest product approved by FDA or in the news. However, before a treatment decision is made, one must understand the clinical data that was used to support the market approval. While placebo-controlled studies may be the gold standard for the FDA approval of a given product....Read More
Moderna and Gilead Teach the “Value for Speed” in Pharma
About a month ago, it was being predicted that a treatment for COVID-19 may take several months and a vaccine may not be available for 12-18 months. These predictions got kicked with the emergency approval of Gilead’s remdesivir, and positive results from Moderna’s vaccine trial run by NIH, and this is not by chance. Read More
Physician’s Perspective in Using Clinical Trials Data in Patient Care
Physicians are often coaxed by their patients to try the latest product approved by FDA or in the news. However, before a treatment decision is made, one must understand the clinical data that was used to support the market approval. While placebo-controlled studies may be the gold standard for the FDA approval of a given product....Read More
